Kornimate/medical-research-clean huggingface dataset:
topical treatment for atopic dermatitis

Conditions: Atopic Dermatitis

Summary: medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. within the united states, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. while the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.

unlike most modes of medication administration, topical medications do not have a standardized method of dosage administration\] although qualitative administration measures exist, these measures are often arbitrary and not quantifiable (i.e., "a fingertip"). in such cases, inappropriate dosing (i.e., using too much or too little) is an essential cause of treatment failure, and measurements of adherence for topical medications should consider the amount of medication administered. in a study analyzing the response to treatment in psoriatic patients, patients who received a standardized dose of topical calcipotriol achieved a more significant decrease in mean psoriasis area and severity index (pasi) (47%) compared to patients who were not standardized (17%, p\<0.0001). moreover, over two-thirds of psoriatic patients deemed initially poor responders in the standardized regimen group were considered responsive to treatment after further consideration. given topical options' low cost, efficacy, and excellent safety profiles, they are the first line treatment option for mild-to-moderate atopic dermatitis (ad) treatment. this study will aim to assess differences in the amount of medication dispensed in two groups of patients with atopic dermatitis. the first will undergo a brief educational demonstration by a trained professional to highlight the appropriate amount of topical medication to dispense for their disease involvement. the second group will be a control group and receive the same medication; however, the participants will receive standard of care education (verbal and written instructions) only. data from the two groups will be collected and analyzed to measure trends in dosing (i.e., if the correct dosage quantity and frequency was dispensed).

Eligibility criteria:
inclusion criteria: * diagnosis of skin dermatitis * age \> 9 * ability to return for a one-week clinical studies follow-up * patients who are candidates for treatment with 0.1% triamcinolone ointment (even if they weren't in the study) * adult or pediatric patients with active dermatitis who receive dermatologic care at atrium health wake forest baptist, department of dermatology. exclusion criteria: * patients without the diagnosis of skin dermatitis * inability to return for a one week follow up appointment * body surface area (bsa) affected \<2%

Keywords: medication adherence topical medications triamcinolone
study to assess the efficacy and safety of rifaximin administered bid in the treatment of patients with diarrhea-associated irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: this is placebo-controlled study of three rifaximin doses in patients with dibs. subjects will be randomized to receive daily doses of placebo bid, rifaximin 275 mg bid, rifaximin 550 mg bid, or 1100 mg bid for 14 days. these four groups will subsequently receive an additional two weeks of placebo for a total of 4 weeks of treatment. a fifth group of subjects will receive rifaximin 550 mg bid for a period of 28 days. subjects who successfully respond to treatment at the end of the 28-day treatment phase will be followed in a post-treatment phase that includes study visits during weeks 6, 8, 12 and 16. subjects who relapse during the post-treatment phase will be discontinued from the study.

while ibs is one of the most common chronic medical conditions the etiology of ibs is unknown. although not a life-threatening illness, ibs is considered to be a serious condition that has a substantial impact on a subject's day-to-day function. ibs is characterized by abdominal pain and altered bowel habits, including diarrhea, constipation, or alternating diarrhea and constipation. symptoms are typically intermittent but may be continuous.

Eligibility criteria:
inclusion criteria: 1. male or female subject 18 years of age or older. 2. irritable bowel syndrome confirmed by the rome ii criteria 3. lower endoscopic examination that demonstrates normal colonic anatomy exclusion criteria: 1. subject has exclusively constipation-predominant ibs (cibs) that is characterized by \< 3 bowel movements/week or hard and lumpy stools. 2. subject has alternating ibs, but is currently presenting with constipation associated ibs symptoms. 3. subject has had adequate control of their dibs and their symptom of bloating the week preceding the screening visit or at the time of randomization. bloating includes the following symptoms: abdominal fullness, bloating, gas, or swelling. 4. subjects has a positive stool culture for o \& p (ovum and parasite) and/or clostridium difficile 5. subject has failed to record 2 negative weekly global assessments during the past 10 days prior to randomization.

Keywords: irritable bowel syndrome
periodontal inflammation and immunity in preclinical rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Periodontal Disease

Summary: the purpose of this study is to evaluate the association of rheumatoid arthritis (ra)-related antibodies and periodontal inflammation in subjects at-risk for rheumatoid arthritis. subjects will undergo periodontal and joint examinations, as well as collection of body fluids to measure rheumatoid arthritis-related antibodies.


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis-antibody positivity (anti-ccp) in the absence of arthritis or * early ra \<36 months since diagnosis exclusion criteria: * pregnancy * antibiotic use prior to dental procedures or cleanings * wear dentures * \<18 years old
evaluate artificial tear efficacy in moderate to severe dry eye

Conditions: Dry Eye

Summary: comparison of two dry eye products


Eligibility criteria:
inclusion: * have a score of at least 2 ("some of the time") on the subject-assessed symptom eligibility question; see section 8.5.1. * have a sodium fluorescein corneal staining sum of ≥ 3 in either eye; see section 8.5.10. * have a best-corrected visual acuity of 0.6 log mar or better in each eye as assessed using an etdrs chart; see section 8.5.7. exclusion: * have a history or current evidence of the following: epithelial herpes simplex keratitis (dendrictic keratitisis); vaccinia, active or recent varicella viral disease of the cornea and/or conjunctiva; ocular rosacea; acute or chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye. * use of restasis® (cyclosporine ophthalmic emulsion, 0.05%) within 30 days of visit 1. * use of systemic medications that may contribute to dry eye if the dosing regimen has not been stable for at least 30 days prior to visit * additionally, the dosing regimen must remain stable throughout the study period. medications known to contribute to dry eye include, but are not limited to, cold and allergy treatments, tricyclic antidepressants, and hormone replacement therapies. * presence of ocular conditions such as active acute blepharitis, conjunctival infections, iritis, or any other ocular condition that may preclude the safe administration of the test article. * unwilling to discontinue contact lens wear at least 7 days prior to visit 1 and during the study period. * current punctal occlusion of any type (e.g., collagen plugs, silicone plugs).

Keywords: dry eye corneal staining
treatment of osteoarthritic knee with high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells.

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to evaluate the clinical results after implantation of human umbilical cord blood-derived mesenchymal stem cells(hucb-mscs) and high tibia osteotomy in patients with medial compartment osteoarthritis(mcoa) as well as varus deformity of the knee joint. this study will prospectively evaluate 10 knees after hucb-mscs implantation and high tibial osteotomy(hto) in the medial compartment osteoarthritis and varus deformity of the knee joint. clinical outcomes will be evaluated using the international knee documentation committee(ikdc), visual analogue scale(vas), western ontario and mcmaster universities arthritis index(womac), and patients satisfaction with the surgery.


Eligibility criteria:
inclusion criteria: * age older than 30 years, * full-thickness cartilage lesion measuring at least 2 cm2, * femoro-tibial angle (varus or valgus) 5°\< in the mechanical axis exclusion criteria: * ligament injuries (such as injuries of the anterior cruciate ligament and posterior cruciate ligament), * metabolic arthritis * infectious condition * psychosis * serious medical illness * pregnancy

Keywords: osteoarthritis knee high tibial osteotomy umbilical cord blood stem cell cartilage regeneration
impact of emotional reactivity on dysfunctional decision-making in nssi adolescents

Conditions: Nonsuicidal Self Injury; Prediction Errors

Summary: nonsuicidal self-injury (nssi) is defined as direct, intentional physical injury without suicidal intention. studies revealed that dysfunctional interpersonal relationships and reward-related decision-making may play crucial roles in this maladaptive behavior, especially in adolescents. these interpersonal decision contexts are characterized by constant updating of expectations of rewards and the actual received rewards as well as the associated emotional reactions. these processes have recently been computationally formalized as prediction errors (pe), specifically reward pes, valence pes, and arousal pes (heffner et al., 2021; nat hum behav). in the current study, the investigators aim to investigate whether these pes make discernible contributions to social decisions in the context of unfair experiences among adolescents with nssi and matched healthy control adolescents (hc). specifically the investigators hypothesized that: 1) reward and emotional pes show significant predictions of punishment decisions in both groups, 2) however, compared to hc adolescents, the nssi group will exhibit selective dysfunctions in emotional but not reward pes leading to punish a norm proposer who provided unfair offers.


Eligibility criteria:
inclusion criteria: * 15-18 years * right-handed * normal or corrected normal visual acuity * meet the proposed dsm-5 frequency criteria (e.g., ≥5 days of nssi behaviors in the past year) exclusion criteria: * diagnosis of borderline personality disorder, major depressive disorder, other * psychiatric disorders, etc. * high suicidal risk * recent use of medications that can affect neural activity * have received or are receiving dialectical behavior therapy (dbt) other treatment for emotional problems within the past 6 months * have a contraindication to mri scanning (e.g., metal implants, claustrophobia or other conditions that make them inappropriate for mri scanning)
compound glutamine enteric-coated capsules combined with thalidomide in preventing radiation-induced oral mucositis

Conditions: Mucositis Oral

Summary: the goal of this study is to compare compound glutamine enteric-coated capsules (cgecc) combined with thalidomide with cgecc in preventing radiation-induced oral mucositis. the aim of this study is to answer whether cgecc plus thalidomide could improve the median incidence time of grade 2 oral mucositis. participants would be randomly divided into the two groups above mentioned.

explore the therapeutic efficacy of cgecc combined with thalidomide as compared to cgecc alone in preventing radiation-induced oral mucositis. the primary research endpoint is the median time to the onset of grade ii oral mucositis, defined as the number of days from the start of radiation therapy to the occurrence of grade ii oral mucositis.

Eligibility criteria:
inclusion criteria: 1. age 18 to 75 years old; 2. patients with postoperative oral malignant tumors confirmed by pathological histology or cytology and requiring radiotherapy; 3. patients who have received more than 45gy of radiation in the oral area; 4. ecog ps (eastern cooperative oncology group performance status) score of 0-1; 5. basic hematological indicators are normal: white blood cell count ≥ 4×10\^9/l; absolute neutrophil count ≥ 1.5×10\^9/l; platelets ≥ 100×10\^9/l; hemoglobin ≥ 90 g/l; 6. basic renal function is normal: serum creatinine ≤ 1.5×uln (upper limit of normal) or creatinine clearance rate (crcl) \> 60 ml/min (using the cockcroft-gault formula): for women: crcl = (140 - age) × weight (kg) × 0.85 / (72 × scr mg/dl) for men: crcl = (140 - age) × weight (kg) × 1.00 / (72 × scr mg/dl) 7. basic liver function is normal: serum total bilirubin ≤ 1.5×uln; ast (aspartate aminotransferase) ≤ 2.5×uln; alt (alanine aminotransferase) ≤ 2.5×uln. 8. signed written informed consent. exclusion criteria: 1. participated in another interventional clinical trial within the last 30 days; 2. patients with severe underlying oral diseases who cannot tolerate radiation therapy; 3. patients allergic to glutamine and thalidomide; 4. patients receiving secondary radiation therapy to the oral area; 5. pregnant women (confirmed by blood or urine hcg testing) or breastfeeding women, or participants of childbearing age who are unwilling or unable to take effective contraceptive measures (applicable to both male and female participants) until at least 6 months after the last trial treatment; 6. patients with underlying peripheral neuropathy; 7. individuals deemed by the researcher to be inappropriate for participation in this study; 8. unwilling to participate in this study or unable to sign informed consent.
roll-over study of ivacaftor in cystic fibrosis pediatric subjects with a cf transmembrane conductance regulator gene (cftr) gating mutation

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to provide information regarding the long-term safety and pharmacodynamics of ivacaftor treatment in the pediatric population younger than 6 years of age with cystic fibrosis (cf) who have a cftr gating mutation in at least 1 allele and will further explore the efficacy of long-term ivacaftor treatment in this population of patients with cf.


Eligibility criteria:
inclusion criteria (ivacaftor arm): 1. completed the last study visit of the treatment period of the previous study (nct01705145) 2. hematology, serum chemistry, and vital signs results on day 1 with no clinically significant abnormalities that would interfere with the study assessments, as judged by the investigator 3. as judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions and the parent or legal guardian should be able to ensure that the subject assents to participation in the study to the degree the subject can assent, and that the subject will comply with and is likely to complete the study as planned inclusion criteria (observational arm): 1. subjects who completed their assigned study drug treatment in the previous study (nct01705145) and elected not to enroll in the ivacaftor arm and subjects who prematurely discontinued treatment in the previous study and received at least 1 dose of study drug treatment in the previous study will be eligible for enrollment in the observational arm. exclusion criteria (ivacaftor arm): 1. subjects who prematurely discontinued from the previous study 2. history of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject 3. subjects with a history of study treatment intolerance as observed in their previous study that, in the opinion of the investigator, might pose an additional risk in administering study drug to the subject 4. subjects receiving commercially-available ivacaftor treatment 5. subject was unable to complete an adequate slit-lamp examination at the last ophthalmologic examination in the previous study exclusion criteria: (observational arm) 1. subjects receiving ivacaftor treatment will not be eligible for enrollment in the observational arm.

Keywords: cystic fibrosis
evaluation of early relapse after mandibular lengthening surgery

Conditions: Mandibular Hypoplasia; Relapse

Summary: the goal of this study is to evaluate whether the use of a bone graft substitute at the osteotomy site will result in better stability and diminish early relapse after mandibular lengthening surgery. the study focuses on the evaluation of the following hypothesis: the use of bone graft substitute at the osteotomy site has an influence on: * the 3-dimensional stability of the osteotomy site * early relapse based in the plasticity of the site

bilateral sagittal split osteotomy (bsso)of the mandible is a surgical procedure used to correct dentofacial discrepancies. post-operative stability is of great concern for cmf (cranio maxillo facial) surgeons as the goal is to achieve optimal functional outcomes, good aesthetic results and satisfaction of patients' concerns. skeletal relapse is a known complication of mandibular lengthening surgery and is divided into two groups; short term or early relapse and long term or late relapse. short term relapse occurs within the first 6 to 8 weeks post-operatively and is due to intersegmental movement at the osteotomy site (osteotomy slippage) and osteosynthesis slippage. late relapse is thought to be caused by progressive condylar resorption, a clinical entity affecting the temporomandibular joint. the rationale to reconstruct the lateral cortical defect resulting from mandibular advancement with bsso with a bone graft substitute lies in the prevention of an unaesthetic notching at the inferior border. the use of a self-hardening, space-occupying paste could add mechanical stability, thus increase 3d-stability at the osteotomy site and prevent early relapse. the use of cone-beam computed tomography (cbct) in the treatment planning and postoperative follow-up of orthognathic patients has provided the surgeons with a new three-dimensional imaging modality to evaluate the postoperative skeletal relapse and postoperative morphologic changes of the condyles. skeletal relapse, as well as positional and dimensional changes of the condyles, can be quantified in three dimensions.

Eligibility criteria:
inclusion criteria: * class ii occlusion of non-syndromic origin, mandibular hypoplasia * availability of pre- and postoperative cbct scans of sufficient quality * age: \>10years exclusion criteria: * previous orthognathic surgical treatment * simultaneously performed genioplasty * plate osteosynthesis * buccal plate fracture during surgery

Keywords: hydroset
comparison of respiratory support for acute pulmonary edema

Conditions: Pulmonary Edema - Acute

Summary: this study is a retrospective study. the demographic and vital signs of patients with acute pulmonary edema are retrospectively collected to compare the prognosis of patients after receiving different respiratory support.


Eligibility criteria:
inclusion criteria: * diagnosis of acute pulmonary edema exclusion criteria: * under 18 years old
internet-delivered cbt for patients with nccp

Conditions: Non-cardiac Chest Pain; Cardiac Anxiety

Summary: non-cardiac chest pain (nccp) is common and has substantial impact on patients' psychological wellbeing, quality of life and healthcare use. although cardiac diagnosis is 'ruled out', many patients think they have an undetected cardiac disease (i.e. they suffer cardiac anxiety) as no other explanation is offered. they therefore avoid activities that they believe might be harmful to their heart, leading to greater ill-health, and increased healthcare use and societal costs. targeting cardiac anxiety with psychological interventions might break this vicious circle and improve patient outcomes. patients need to evaluate the way they perceive and handle their chest pain, which can be done with cognitive behavioral therapy (cbt). the aim of this study is therefore to evaluate the short- and long-term effects of an internet-delivered cbt (i-cbt) program on psychological distress and other patient-reported outcomes in patients with nccp. a second aim is to explore factors related to implementation of i-cbt in clinical care. the study has a randomized controlled design comparing i-cbt with internet-delivered information program. quantitative methods will be used to evaluate the effectiveness of the i-cbt program. implementation issues will be evaluated from the perspectives of patients, healthcare professionals and policymakers using qualitative methods.


Eligibility criteria:
inclusion criteria: * at least 2 healthcare visits due to nccp during the last 6 months * patients suffering from cardiac anxiety (score ≥ 24 on the cardiac anxiety questionnaire-caq) exclusion criteria: * language difficulties * not able to perform physical activity/exercise due to physical constraints * patients with severe depressive symptoms * patients with acute ischemic heart disease * patients with no access to computer/tablet and/or internet

Keywords: non-cardiac chest pain psychological distress i-cbt
ranibizumab intravitreal injections versus sham control in patients with central retinal vein occlusion (crvo)

Conditions: Central Retinal Vein Occlusion

Summary: provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to crvo


Eligibility criteria:
inclusion criteria for study and fellow eye: • patients with visual impairment secondary to central retinal vein occlusion (crvo) with a bcva between 24 and 73 letters in one eye and at least 35 letters in the other eye. exclusion criteria: * pregnant or nursing women or women of child bearing potential unless using an effective contraception - stroke or myocard infarction within 3 months prior to study * history of malignancy within the past 5 years * uncontrolled hypertension * active infection or inflammation in any eye * use of corticosteroids for at least 30 days in the last 6 months * treatment with anti-angiogenic drugs in any eye within last 3 months * panretinal or focal/drid laser photocoagulation within the last 3 and 4 months respectively

Keywords: crvo, macular edema, vision impairment, retinal vein occlusion, ranibizumab